ArticleACS applied materials & interfaces2025
Strategic Secondary Ligand Selection for Enhanced Pore-Type Construction and Water Purification Capacity in Zeolitic Imidazolate Frameworks.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multifunctional FePharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective ligand removal (SeLiRe) is a powerful strategy for constructing novel pore-type and ligand-defective structures in metal-organic frameworks (MOFs), but few studies have focused on the effect of secondary ligands with different functional groups on this process. We synthesized versions of zeolitic imidazolate framework-8 with six different secondary ligands and comprehensively investigated their pore-type structures after SeLiRe treatment. Their pore volume, size, and distribution are closely related to the respective organic functional groups on the secondary ligands. NH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.